Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

Official Title

Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi

Brief Summary

      This study will investigate sleep behavior in subjects with Angelman Syndrome, Rett Syndrome
      or Prader-Willi Syndrome.

      The study will also investigate sleep behavior in healthy siblings of subjects with Angelman
      Syndrome, Rett Syndrome or Prader-Willi Syndrome. These individuals will serve as control
      subjects.

      The study will use questionnaires designed to identify sleep disorders and how they affect
      behavior and quality of life.

      The principal goals of this study are:

        1. To see how common sleep disorders are in individuals with Angelman Syndrome, Rett
           Syndrome or Prader-Willi Syndrome;

        2. To see how sleep disorders affect behavior in these individuals;

        3. To see whether sleep disorders and related behavior problems improve or worsen with age;

        4. To see how specific disease conditions relate to sleep disorders and how bad the sleep
           disorders are;

        5. To develop new treatment options to improve quality of life and behavior issues; and

        6. To evaluate current treatment options to improve sleep problems in these individuals.
    

Detailed Description

      Subjects with AS, RTT or PWS and normal siblings (controls) will be recruited for study
      participation.

      Subjects will be recruited from the Rare Disease Clinical Research Network (RDCRN) consortium
      registries for AS, RTT and PWS. The RDCRN registries provide listings of individuals
      currently enrolled in the RDCRN along with clinical and genetic diagnosis, medical history
      and contact information.

      The RDCRN consortium sites for AS, RTT and PWS will participate in the study. These sites
      will recruit study participants, obtain informed consent and administer the sleep
      questionnaires. Institutional Review Board (IRB) approval will be obtained at each RDCRN
      consortium site.

      "Subjects" is defined as those children with a diagnosis of AS, PWS, and RTT. Subjects will
      be divided into separate study arms based upon their medical diagnosis. Study arms will
      consist of: 1) AS group, 2) PWS group, 3) RTT group, and 4) control group. "Control group" is
      defined as normal healthy siblings of subjects.

      Study participants and parents/guardians will be asked to complete the study questionnaires
      during the clinic visit. The questionnaires are brief and should not be difficult to
      complete. It is anticipated that the questionnaires can be completed in 15-30 minutes. If
      parents are unable to complete the questionnaires at the time of their scheduled clinic visit
      they will be asked to take the questionnaires home to complete and to mail them back to the
      research team. When the research team receives the returned questionnaires they will be
      reviewed for completion. If questions are skipped or left blank, a member of the research
      team will call the family to complete the missed questions over the phone.

      Parents/guardians are allowed to answer the questions on behalf of the study participants and
      will be asked to answer all the questions for each age-appropriate questionnaire in order for
      the responses to be scored correctly. Subjects with AS, RTT and PWS and normal siblings will
      complete the same questionnaire forms.

      Study participants will be administered the questionnaires again in 12-24 months at a
      follow-up RDCRN clinic visit or by mail to assess the natural history of their sleep behavior
      and any sleep disorders.

      Study participants identified as having a potential severe sleep disorder based on
      questionnaire responses will be contacted or sent a letter by the study investigators and
      advised to see a sleep specialist for further evaluation.

      Potential "Subjects" must be members of the RDCRN consortium registries with available
      contact and clinical diagnostic information on file. These individuals will be invited to
      participate in the study at their next regularly scheduled RDCRN visit.

      Study recruitment will continue for one year. Subjects with a clinical diagnosis of AS, RTT
      or PWS, or normal siblings of these individuals will be recruited for study participation.

      The sample size of study participants, including controls, will be based upon the number of
      individuals currently enrolled in the RDCRN consortium registries. Currently the combined
      number of individuals in the AS, RTT and PWS RDCRN consortium registries is 1082. The
      breakdown by disorder is: 678 RTT, 172 AS, 141 PWS. Final sample size will be the total
      number of subjects consented during the one year recruitment period. A projected enrollment
      total would be approximately 1,000 total individuals ( 500 subjects including 300 RTT, 100
      AS, 100 PWS & 500 controls).
    


Study Type

Observational


Primary Outcome

Change in sleep behavior as measured by the child's sleep habits questionnaire (CSHQ) for Rett Syndrome, Angleman and control group

Secondary Outcome

 Pediatric Sleep Questionnaire (PSQ) - Sleep Disordered Breathing Subscale

Condition

Rett Syndrome


Study Arms / Comparison Groups

 Rett Syndrome
Description:  Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

804

Start Date

June 2011

Completion Date

July 2013

Primary Completion Date

July 2013

Eligibility Criteria

        Inclusion Criteria:

        Eligible Inclusion Criteria - Subjects

          1. Enrollment in a RDCRN consortium registry for either AS, RTT or PWS.

          2. Have a clinical diagnosis of AS, RTT or PWS, or be a normal sibling of an individual
             with AS, RTT or PWS who is enrolled in the study.

          3. Be between 0 to18 years of age inclusive.

          4. Be English-speaking (study questionnaires will only be available in English).

        Inclusion Criteria - Controls

          1. Must have a sibling with either AS, RTT or PWS enrolled in the study.

          2. Must not have a diagnosis of any neurological disorder.

          3. Be between 0 to18 years of age inclusive

          4. Be English-speaking (study questionnaires will only be available in English).

        Exclusion Criteria:

        Exclusion Criteria - Subjects

          1. No clinical diagnosis of AS, RTT, or PWS.

          2. Diagnosis of a severe genetic disorder in addition to AS, RTT, or PWS.

          3. Be over 18 years of age inclusive.

        Exclusion Criteria - Controls

          1. Diagnosis of a neurological disorder.

          2. Diagnosis of a severe genetic disorder.

          3. Be over 19 years of age inclusive.
      

Gender

All

Ages

1 Year - 18 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Daniel Glaze, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02670694

Organization ID

H-26535


Responsible Party

Principal Investigator

Study Sponsor

Baylor College of Medicine

Collaborators

 Boston Children's Hospital

Study Sponsor

Daniel Glaze, MD, Study Chair, Baylor College of Medicine


Verification Date

January 2016